A Decade of Percutaneous Coronary Interventions in Cardiac Transplant Recipients: A Monocentric Study in 160 Patients

Journal of Heart and Lung Transplantation

Volumn 27, Issue 1, 2008, Pages 17-25

  Wellnhofer, Ernst ^a   Hiemann, Nicola E ^a   Hug, Jürgen ^a   Dreysse, Stefan ^a   Knosalla, Christoph ^a   Graf, Kristof ^a   Meyer, Rudolph ^a   Lehmkuhl, Hans B ^a   Hetzer, Roland ^a   Fleck, Eckart ^a  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CLOPIDOGREL; CYCLOSPORIN A; MEPREDNISONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ADULT; ARTICLE; CARDIAC GRAFT REJECTION; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DRUG ELUTING STENT; FEMALE; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RESTENOSIS; REVASCULARIZATION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BLOOD VESSEL PROSTHESIS IMPLANTATION; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ANGIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GRAFT OCCLUSION, VASCULAR; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 37549051334     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2007.10.007     Document Type: Article

References (50)

1. Taylor D.O., Edwards L.B., Boucek M.M., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report-2006. J Heart Lung Transplant 25 (2006) 869-879
2. Billingham M.E. Graft coronary disease: the lesions and the patients. Transplant Proc 21 (1989) 3665-3666
3. von Scheidt W., Kemkes B.M., Reichart B., and Erdmann E. Percutaneous transluminal coronary angioplasty of focal coronary lesions after cardiac transplantation. Clin Investig 71 (1993) 524-530
4. Vetrovec G.W., Cowley M.J., Newton C.M., et al. Applications of percutaneous transluminal coronary angioplasty in cardiac transplantation. Preliminary results in five patients. Circulation 78 (1988) III83-III86
5. Swan J.W., Norell M., Yacoub M., Mitchell A.G., and Ilsley C. Coronary angioplasty in cardiac transplant recipients. Eur Heart J 14 (1993) 65-70
6. Mullins P.A., Shapiro L.M., Aravot D.A., et al. Experience of percutaneous transluminal coronary angioplasty in orthotopic cardiac transplant recipients. Eur Heart J 12 (1991) 1205-1207
7. Halle III A.A., Wilson R.F., Massin E.K., et al. Coronary angioplasty in cardiac transplant patients. Results of a multicenter study. Circulation 86 (1992) 458-462
8. Christensen B.V., Meyer S.M., Iacarella C.L., Kubo S.H., and Wilson R.F. Coronary angioplasty in heart transplant recipients: a quantitative angiographic long-term follow-up study. J Heart Lung Transplant 13 (1994) 212-220
9. Bader F.M., Kfoury A.G., Gilbert E.M., et al. Percutaneous coronary interventions with stents in cardiac transplant recipients. J Heart Lung Transplant 25 (2006) 298-301
10. Benza R.L., Zoghbi G.J., Tallaj J., et al. Palliation of allograft vasculopathy with transluminal angioplasty: a decade of experience. J Am Coll Cardiol 43 (2004) 1973-1981
11. Doshi A.A., Rogers J., Kern M.J., and Hauptman P.J. Effectiveness of percutaneous coronary intervention in cardiac allograft vasculopathy. Am J Cardiol 93 (2004) 90-92
12. Pethig K., Heublein B., and Haverich A. Cardiac allograft vasculopathy-coronary interventions and surgical options. Z Kardiol 89 suppl 9 (2000) IX/66-9
13. Simpson L., Lee E.K., Hott B.J., Vega D.J., and Book W.M. Long-term results of angioplasty vs stenting in cardiac transplant recipients with allograft vasculopathy. J Heart Lung Transplant 24 (2005) 1211-1217
14. Tanaka K., Li H., Curran P.J., et al. Usefulness and safety of percutaneous coronary interventions for cardiac transplant vasculopathy. Am J Cardiol 97 (2006) 1192-1197
15. Aranda J.M., Pauly D.F., Kerensky R.A., et al. Percutaneous coronary intervention versus medical therapy for coronary allograft vasculopathy. One center's experience. J Heart Lung Transplant 21 (2002) 860-866
16. Halle III A.A., DiSciascio G., Massin E.K., et al. Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. J Am Coll Cardiol 26 (1995) 120-128
17. Dandel M., Hummel M., Muller J., et al. Reliability of tissue Doppler wall motion monitoring after heart transplantation for replacement of invasive routine screenings by optimally timed cardiac biopsies and catheterizations. Circulation 104 12 suppl 1 (2001) I184-I191
18. Billingham M.E., Cary N.R.B., Hammond M.E., et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. J Heart Lung Transplant 9 (1990) 587-593
19. Schnetzler B., Drobinski G., Dorent R., et al. The role of percutaneous transluminal coronary angioplasty in heart transplant recipients. J Heart Lung Transplant 19 (2000) 557-565
20. Syeda B., Roedler S., Schukro C., Yahya N., Zuckermann A., and Glogar D. Transplant coronary artery disease: Incidence, progression and interventional revascularization. Int J Cardiol 104 (2005) 269-274
21. Jonas M., Fang J.C., Wang J.C., et al. In-stent restenosis and remote coronary lesion progression are coupled in cardiac transplant vasculopathy but not in native coronary artery disease. J Am Coll Cardiol 48 (2006) 453-461
22. Halle III A.A., Wilson R.F., and Vetrovec G.W. Multicenter evaluation of percutaneous transluminal coronary angioplasty in heart transplant recipients. Cardiac Transplant Angioplasty Study Group. J Heart Lung Transplant 11 (1992) S138-S141
23. Heublein B., Pethig K., Maass C., Wahlers T., and Haverich A. Coronary artery stenting in cardiac allograft vascular disease. Am Heart J 134 (1997) 930-938
24. Tham E.B., Yeung A.C., Cheng C.W., Bernstein D., Chin C., and Feinstein J.A. Experience of percutaneous coronary intervention in the management of pediatric cardiac allograft vasculopathy. J Heart Lung Transplant 24 (2005) 769-773
25. Kobashigawa J.A., Moriguchi J.D., Laks H., et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant 24 (2005) 1736-1740
26. Abele S., Weyand M., Wollin M., et al. Clopidogrel reduces the development of transplant arteriosclerosis. J Thorac Cardiovasc Surg 131 (2006) 1161-1166
27. Eisen H.J., Kobashigawa J., Keogh A., et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 24 (2005) 517-525
28. Kobashigawa J.A., Tobis J.M., Mentzer R.M., et al. Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: reanalysis of the multicenter trial. Am J Transplant 6 (2006) 993-997
29. Park D.W., Hong M.K., Mintz G.S., et al. Two-year follow-up of the quantitative angiographic and volumetric intravascular ultrasound analysis after nonpolymeric paclitaxel-eluting stent implantation: late "catch-up" phenomenon from ASPECT Study. J Am Coll Cardiol 48 (2006) 2432-2439
30. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
31. Hofma S.H., van der Giessen W.J., van Dalen B.M., et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 27 (2006) 166-170
32. Hognestad A., Endresen K., Wergeland R., et al. Inflammatory response and re-stenosis after percutaneous coronary intervention in heart transplant recipients and patients with native atherosclerosis. J Heart Lung Transplant 24 (2005) 1026-1032
33. Topaz O., Janin Y., Bernardo N., Bailey N.T., and Mohanty P.K. Coronary revascularization in heart transplant recipients by excimer laser angioplasty. Lasers Surg Med 26 (2000) 425-431
34. Musci M., Loebe M., Wellnhofer E., et al. Coronary angioplasty, bypass surgery, and retransplantation in cardiac transplant patients with graft coronary disease. Thorac Cardiovasc Surg 46 (1998) 268-274
35. Kobashigawa J.A., and Meiser B.M. Review of major clinical trials with mycophenolate mofetil in cardiac transplantation. Transplantation 80 2 suppl (2005) S235-S243
36. Felkel T.O., Smith A.L., Reichenspurner H.C., et al. Survival and incidence of acute rejection in heart transplant recipients undergoing successful withdrawal from steroid therapy. J Heart Lung Transplant 21 (2002) 530-539
37. Ratkovec R.M., Wray R.B., Renlund D.G., et al. Influence of corticosteroid-free maintenance immunosuppression on allograft coronary artery disease after cardiac transplantation. J Thorac Cardiovasc Surg 100 (1990) 6-12
38. Rosenbaum D.H., Adams B.C., Mitchell J.D., et al. Effects of early steroid withdrawal after heart transplantation. Ann Thorac Surg 82 (2006) 637-644
39. Taylor D.O., Bristow M.R., O'Connell J.B., et al. Improved long-term survival after heart transplantation predicted by successful early withdrawal from maintenance corticosteroid therapy. J Heart Lung Transplant 15 (1996) 1039-1046
40. Eisen H., Kobashigawa J., Starling R.C., Valantine H., and Mancini D. Improving outcomes in heart transplantation: the potential of proliferation signal inhibitors. Transplant Proc 37 4 suppl (2005) 4S-17S
41. Kobashigawa J.A., and Patel J.K. Immunosuppression for heart transplantation: where are we now?. Nat Clin Pract Cardiovasc Med 3 (2006) 203-212
42. Eisen H.J., Tuzcu E.M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349 (2003) 847-858
43. Valantine H. Prevention of cardiac allograft vasculopathy with Certican (everolimus): the Stanford University experience within the Certican Phase III clinical trial. J Heart Lung Transplant 24 4 suppl (2005) S191-S195
44. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333 (1995) 621-627
45. Mehra M.R., Uber P.A., Vivekananthan K., et al. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. J Am Coll Cardiol 40 (2002) 1609-1614
46. Fateh-Moghadam S., Bocksch W., Ruf A., et al. Changes in surface expression of platelet membrane glycoproteins and progression of heart transplant vasculopathy. Circulation 102 (2000) 890-897
47. Graff J., Klinkhardt U., Schini-Kerth V.B., et al. Close relationship between the platelet activation marker CD62 and the granular release of platelet-derived growth factor. J Pharmacol Exp Ther 300 (2002) 952-957
48. Klinkhardt U., Graff J., and Harder S. Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model. Clin Pharmacol Ther 71 (2002) 176-185
49. Klinkhardt U., Bauersachs R., Adams J., Graff J., Lindhoff-Last E., and Harder S. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther 73 (2003) 232-241
50. Potluri S.P., Mehra M.R., Uber P.A., Park M.H., Scott R.L., and Ventura H.O. Relationship among epicardial coronary disease, tissue myocardial perfusion, and survival in heart transplantation. J Heart Lung Transplant 24 (2005) 1019-1025